Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
6.54%
operating margin TTM
7.74%
revenue TTM
71.47 Million
revenue per share TTM
0.9$
valuation ratios | |
|---|---|
| pe ratio | 29.41 |
| peg ratio | 0.29 |
| price to book ratio | 2.54 |
| price to sales ratio | 2.00 |
| enterprise value multiple | 18.66 |
| price fair value | 2.54 |
profitability ratios | |
|---|---|
| gross profit margin | 49.97% |
| operating profit margin | 7.74% |
| pretax profit margin | 8.63% |
| net profit margin | 6.54% |
| return on assets | 5.29% |
| return on equity | 10.46% |
| return on capital employed | 9.34% |
liquidity ratio | |
|---|---|
| current ratio | 2.49 |
| quick ratio | 1.69 |
| cash ratio | 0.80 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 238.14 |
| operating cycle | 266.69 |
| days of payables outstanding | 50.31 |
| cash conversion cycle | 216.38 |
| receivables turnover | 12.78 |
| payables turnover | 7.25 |
| inventory turnover | 1.53 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.07 |
| debt equity ratio | 0.12 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.10 |
| interest coverage | 6.83 |
| cash flow to debt ratio | -0.11 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.02 |
| cash per share | 0.45 |
| operating cash flow per share | -0.01 |
| free cash flow operating cash flow ratio | 2.73 |
| cash flow coverage ratios | -0.11 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -0.58 |
Frequently Asked Questions
When was the last time Protalix BioTherapeutics, Inc. (AMEX:PLX) reported earnings?
Protalix BioTherapeutics, Inc. (PLX) published its most recent earnings results on 09-05-2025.
What is Protalix BioTherapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Protalix BioTherapeutics, Inc. (AMEX:PLX)'s trailing twelve months ROE is 10.46%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Protalix BioTherapeutics, Inc. (PLX) currently has a ROA of 5.29%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did PLX's net profit margin stand at?
PLX reported a profit margin of 6.54% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is PLX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.49 in the most recent quarter. The quick ratio stood at 1.69, with a Debt/Eq ratio of 0.12.